Health. Psoriasis: a Major Discovery Paves the Way for Tailor-Made Treatment

조선일보

Lean Right

Factuality

Ownership

Celltrion announced on the 24th that it has applied to the European Medicines Agency for marketing authorization of its psoriasis treatment, CT-P55. This is a biosimilar of Cosentyx, developed by the Swiss pharmaceutical company Novartis. If it clears the hurdle of European approval, it is expected to be available for prescription to patients with psoriasis, psoriatic arthritis, ankylosing spondylitis, and other conditions. Previous clinical tri…

leprogres.fr

bienpublic.com

View article

Reposted by

bienpublic.com

Center

Factuality

Ownership

Why are some people suffering from psoriasis refractory to all the therapeutics, including the latest biotherapies? An international consortium of researchers, coordinated by the French Hervé Bachelez, finally holds an explanation: a rare mutation has been discovered in these patients, with impressive responses to the drugs targeting the involved inflammatory pathway.